Exciting research in the field of liver cancer
1.Levastinil is expected to become the new standard for treating advanced liver cancer
ASCO annual meeting report this year happy felling for his head butt sorafenib first-line treatment liver cancer international phase III clinical study, REFLECT the results of the study happy felling for, to survive in the primary end point total OS to achieve expected results, secondary end points progression-free survival (PFS), development time (TTP) and the objective response rate (ORR) full beyond sorafenib.
The study was a randomized, open, nonsubstandard (NI) study that confirmed that the effects of levatinib on the treatment of advanced liver cancer were not inferior to sorafenib.
The study of REFLECT began in 2013, with 954 cases of late/unresected HCC patients, greater than 1 target lesion, Barcelona staging B or C, child-pugh A, ECOG PS of less than 1, prior to treatment.
Patients were randomly assigned to the levarinib group (478 cases) and sorafenib (476 cases).
The main research endpoint was OS, and the Cox proportional risk model was used to estimate the HR and 95% CI of OS, and the preset NI edge was 1.08.
The secondary endpoint is PFS, TTP and ORR, and the evaluation method is mRECIST.
The primary endpoint of the OS levartiinib group had an extended trend, the secondary end of the levarinib group was significantly superior to sorafenib group, PFS (7.4 m VS 3.7 m), TTP (8.9 m VS 3.7 m), ORR (24% VS 9%).
Although no statistically differences REFLECT study two groups of the primary end point, but we can see a happy felling for group, PFS is sorafenib group 2 times, 3 times of TTP is extended to sorafenib.
This means that the patients in the levastinib group had a longer and more effective control time, and the patients with better baseline conditions were better at using levatinib.
The favorable TTP results of levartini have brought some potential options for advanced liver cancer, and may be used to combine with other treatments in the future to give patients a longer survival time.
At the same time happy felling for ORR's group is sorafenib group, nearly three times as high objective response rate is helpful for doctors to judge drug effectiveness, reduce the tumor load at the same time, to improve the quality of life of patients is associated with tumor.
2.Capecitabine reduces the recurrence of biliary tract tumor (BTC) and prolongs survival
The ASCO annual meeting, for the treatment of biliary tract cancers research also has some of the more impressive is the British researchers conducted a card times he marina, reduce the recurrence of BTC correlation studies through a multicenter randomized controlled trials, evaluating BTC patients undergoing radical surgery (or R1 R0 resection), capecitabine (when Rhoda) whether the adjuvant therapy can reduce recurrence and prolong survival.
Research has raised a total of 447 patients, including intrahepatic bile duct carcinoma (iCCA, 19%), hepatic portal vein, bile duct carcinoma (28%), extrahepatic bile duct carcinoma (35%), and muscle layer of gallbladder (18%), according to the proportion of 1:1 random capecitabine treatment or simply observed.
The main end point (ITT analysis method), capecitabine can improve patients' OS (51 vs 36 months, HR = 0.80, P = 0.097), and the corrected HR = 0.71 (P < 0.01);
If per - protocol analysis, capecitabine significantly improved OS (53 vs 36 months, HR = 0.75, P = 0.028).
The RFS is also more excellent in the carpe-bin group (the ITT analysis method, 25 vs 18 months).
There are many breakthrough studies in this conference, but the study of adjuvant therapy after hepatobiliary tumor is still lacking.
The good results obtained by the study of the BTC at BTC are a bright beacon for the treatment of liver cancer.
prev:Exciting research in the field of lung cancer(2017-07-03)
next:Exciting research in breast cancer(2017-07-04)